DNBSEQ-T7+ by Complete Genomics (MGI Tech): status and timeline

Milestones

Next · Major US lab deployments of T7+

DNBSEQ-T7+ releasedFeb 2026Complete.
FDA clearance for US saleFeb 2026Complete.
Commercial availability in USFeb 2026Complete.

Most important updates

Complete Genomics releases DNBSEQ-T7+ high-throughput sequencer for US market at $100/genome costFeb 2026

Upcoming

2027Major US lab deployments of T7+ (next)

Current obstacles

Dislodge NovaSeq installed baseIllumina owns most NovaSeq systems with integrated analysis workflows. Complete Genomics must match support.
Build US lab relationshipsFDA clearance alone doesn't guarantee adoption. Relationships with major research centers and clinical labs take time.

Physics limits

Short-read sequencing cannot resolve complex structural variantsLike all short-read systems, T7+ struggles with repetitive regions and large structural variants. Long-read sequencers (PacBio, Oxford Nanopore) excel there.
$800k cost limits adoptionOnly core facilities can afford T7+. Smaller labs use service providers or cheaper platforms.

How it works

3 parts

Nanoball packing

High-density amplification

DNA is amplified into tight nanoscale balls on the flow cell for high effective depth per unit area.

Flexibility

Run time and read length options

Labs choose 14-24 hour runs and 2x75 to 2x150bp reads to fit their project needs.

Scale economics

Cost per sample drops with volume

High-volume labs running cancer genomics and population screening get lowest per-sample cost.

Spec sheet

Spec	DNBSEQ-T7+
Data per 24-hour run	14+ Terabases (Tb)^R (reported)
Human genomes per day	144^R (reported)
Cost per human genome	~$100^E (estimated)
Instrument MSRP (August 2026)	$800,000^R (reported)
Read length options	2x75bp to 2x150bp^R (reported)
Run time	14-24 hours^R (reported)
Minimum data quality	≥90% bases at Q40^R (reported)
Maximum output per run	3,600 Gb^R (reported)
Capacity at launch (estimated)	28,000 genomes/year^E (estimated)

^R reported by the company · ^E our estimate

Update log

1 update

Feb 2026

Major: Complete Genomics releases DNBSEQ-T7+ high-throughput sequencer for US market at $100/genome costPressHardware

About Complete Genomics (MGI Tech)

The team behind DNBSEQ-T7+

Complete Genomics (MGI Tech)

DNBSEQ-T7+ sequencer, high-throughput sequencing, $100 genome

Complete Genomics, headquartered in San Jose and owned by MGI Tech (China), builds high-throughput sequencing. DNBSEQ-T7+ (Feb 2026) sequences 144 human genomes in 24 hours at ~$100 each. US available after FDA clearance.

Complete Genomics pioneered whole-genome sequencing; MGI now owns and scales it.
T7+ (Feb 2026): 144 human genomes in 24 hours at ~$100 per genome.
US available Feb 2026, competing directly with Illumina NovaSeq.

completegenomics.com (opens completegenomics.com)Company profile →

Founded: 200620 yrs
Headquarters: United States
Status: Private
Valuation: private
Staff: ~421Dec 2025
Works in: BiotechGenomics & sequencing
Coverage: 2 programs · 1 updatelatest 1 Feb 2026checked 11 Oct
Acquired by: MGI Tech (opens mgitech.com)

Spec

DNBSEQ-T7+

Data per 24-hour run

14+ Terabases (Tb)^R (reported)

Human genomes per day

144^R (reported)

Cost per human genome

~$100^E (estimated)

Instrument MSRP (August 2026)

$800,000^R (reported)

Read length options

2x75bp to 2x150bp^R (reported)

Run time

14-24 hours^R (reported)

Minimum data quality

≥90% bases at Q40^R (reported)

Maximum output per run

3,600 Gb^R (reported)

Capacity at launch (estimated)

28,000 genomes/year^E (estimated)